KEI Industries (NSE:KEI) Q2 FY27 Results and FDC Buyback Plan Explained
NiveshIQ
NSE: FDC · Healthcare
FDC Ltd.
₹340.45▲ ₹0.80 (+0.24%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on FDC. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About FDC Ltd.
FDC Limited is a diversified Indian pharmaceutical company that designs, manufactures, and markets a broad portfolio of formulations across anti‑infectives, gastroenterology, ophthalmology, anti‑diabetics, cardiovascular, respiratory, gynaecology, dermatology, paediatrics, analgesics, vitamins, and nutritional health. The company’s revenue mix is heavily weighted toward branded generics, with key brands such as Zifi, Zocon, and Victofol driving sales, while its functional food segment contributes a growing share through products like electrolyte drinks and vitamin‑enriched supplements. In FY27, FDC reported revenue of ₹2,190 cr and net income of ₹293 cr, reflecting a modest margin expansion driven by cost efficiencies and higher pricing power in core therapeutic areas. Recent developments
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,943 Cr +8.92% | ₹2,108 Cr +8.50% | ₹2,171 Cr +2.98% |
| EBITDA Margin | 17.42% | 15.41% | 15.94% |
| Net Profit | ₹305.22 Cr +57.30% | ₹266.79 Cr -12.59% | ₹281.42 Cr +5.49% |
| EPS | ₹18.58 | ₹16.39 | ₹17.29 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
FDC NSE:FDC Regulation 74(5) Demat Certificate Q2 FY27
FDC Limited (FDC.NS) Slips Over 3% to ₹339.4 as Pharma Stock Tests Key Support Zone - Key Reversal Day
🔒
+ 2 more stories about FDC Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹572 Cr, PAT ₹50 Cr, EPS ₹3.01, EBITDA margin 11.2%. Growth context: revenue YoY +21.0%, PAT YoY +76.3%, revenue QoQ -14.3%, PAT QoQ -62.2%.
Management highlights order wins, deal pipeline, and backlog build as the key near‑term growth levers, with execution on...
FY26 (last completed FY): revenue ₹2, 171 Cr, PAT ₹281 Cr, EBITDA margin 15.9%, EPS ₹17.29. Year-on-year: revenue YoY +3...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for FDC
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track FDC alongside your other holdings
Unlock full FDC research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for FDC Ltd.?
NiveshIQ detects active intelligence signals for FDC Ltd. (FDC) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for FDC Ltd.?
FDC Ltd. operates in the Healthcare sector with a market capitalisation of ₹554,286.9L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.